1. Home
  2. XOMAP vs PFLT Comparison

XOMAP vs PFLT Comparison

Compare XOMAP & PFLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • XOMAP
  • PFLT
  • Stock Information
  • Founded
  • XOMAP N/A
  • PFLT N/A
  • Country
  • XOMAP United States
  • PFLT United States
  • Employees
  • XOMAP 13
  • PFLT N/A
  • Industry
  • XOMAP Biotechnology: Pharmaceutical Preparations
  • PFLT Finance: Consumer Services
  • Sector
  • XOMAP Health Care
  • PFLT Finance
  • Exchange
  • XOMAP Nasdaq
  • PFLT Nasdaq
  • Market Cap
  • XOMAP N/A
  • PFLT N/A
  • IPO Year
  • XOMAP N/A
  • PFLT N/A
  • Fundamental
  • Price
  • XOMAP $25.80
  • PFLT $11.38
  • Analyst Decision
  • XOMAP
  • PFLT Buy
  • Analyst Count
  • XOMAP 0
  • PFLT 1
  • Target Price
  • XOMAP N/A
  • PFLT $12.50
  • AVG Volume (30 Days)
  • XOMAP N/A
  • PFLT 837.7K
  • Earning Date
  • XOMAP N/A
  • PFLT 08-07-2024
  • Dividend Yield
  • XOMAP N/A
  • PFLT 10.77%
  • EPS Growth
  • XOMAP N/A
  • PFLT N/A
  • EPS
  • XOMAP N/A
  • PFLT 1.54
  • Revenue
  • XOMAP N/A
  • PFLT $155,774,000.00
  • Revenue This Year
  • XOMAP N/A
  • PFLT $14.65
  • Revenue Next Year
  • XOMAP N/A
  • PFLT $23.17
  • P/E Ratio
  • XOMAP N/A
  • PFLT $7.42
  • Revenue Growth
  • XOMAP N/A
  • PFLT 29.37
  • 52 Week Low
  • XOMAP N/A
  • PFLT $9.69
  • 52 Week High
  • XOMAP N/A
  • PFLT $12.63
  • Technical
  • Relative Strength Index (RSI)
  • XOMAP 55.73
  • PFLT 40.13
  • Support Level
  • XOMAP $25.32
  • PFLT $11.15
  • Resistance Level
  • XOMAP $26.00
  • PFLT $11.54
  • Average True Range (ATR)
  • XOMAP 0.36
  • PFLT 0.17
  • MACD
  • XOMAP -0.02
  • PFLT -0.06
  • Stochastic Oscillator
  • XOMAP 55.37
  • PFLT 25.86

About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock

XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.

Share on Social Networks: